RT Journal Article
SR Electronic
T1 Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.03.24309466
DO 10.1101/2024.07.03.24309466
A1 Strom, Nora I.
A1 Verhulst, Brad
A1 Bacanu, Silviu-Alin
A1 Cheesman, Rosa
A1 Purves, Kirstin L.
A1 Gedik, Hüseyin
A1 Mitchell, Brittany L.
A1 Kwong, Alex S.
A1 Faucon, Annika B.
A1 Singh, Kritika
A1 Medland, Sarah
A1 Colodro-Conde, Lucia
A1 Krebs, Kristi
A1 Hoffmann, Per
A1 Herms, Stefan
A1 Gehlen, Jan
A1 Ripke, Stephan
A1 Awasthi, Swapnil
A1 Palviainen, Teemu
A1 Tasanko, Elisa M.
A1 Peterson, Roseann E.
A1 Adkins, Daniel E.
A1 Shabalin, Andrey A.
A1 Adams, Mark J.
A1 Iveson, Matthew H.
A1 Campbell, Archie
A1 Thomas, Laurent F.
A1 Winsvold, Bendik S.
A1 Drange, Ole Kristian
A1 Børte, Sigrid
A1 ter Kuile, Abigail R.
A1 Nguyen, Tan-Hoang
A1 Meier, Sandra M.
A1 Corfield, Elizabeth C.
A1 Hannigan, Laurie
A1 Levey, Daniel F.
A1 Czamara, Darina
A1 Weber, Heike
A1 Choi, Karmel W.
A1 Pistis, Giorgio
A1 Couvy-Duchesne, Baptiste
A1 Van der Auwera, Sandra
A1 Teumer, Alexander
A1 Karlsson, Robert
A1 Garcia-Argibay, Miguel
A1 Lee, Donghyung
A1 Wang, Rujia
A1 Bjerkeset, Ottar
A1 Stordal, Eystein
A1 Bäckmann, Julia
A1 Salum, Giovanni A.
A1 Zai, Clement C.
A1 Kennedy, James L.
A1 Zai, Gwyneth
A1 Tiwari, Arun K.
A1 Heilmann-Heimbach, Stefanie
A1 Schmidt, Börge
A1 Kaprio, Jaakko
A1 Kennedy, Martin M.
A1 Boden, Joseph
A1 Havdahl, Alexandra
A1 Middeldorp, Christel M.
A1 Lopes, Fabiana L.
A1 Akula, Nirmala
A1 McMahon, Francis J.
A1 Binder, Elisabeth B.
A1 Fehm, Lydia
A1 Ströhle, Andreas
A1 Castelao, Enrique
A1 Tiemeier, Henning
A1 Stein, Dan J.
A1 Whiteman, David
A1 Olsen, Catherine
A1 Fuller, Zachary
A1 Wang, Xin
A1 Wray, Naomi R.
A1 Byrne, Enda M.
A1 Lewis, Glyn
A1 Timpson, Nicholas J.
A1 Davis, Lea K.
A1 Hickie, Ian B.
A1 Gillespie, Nathan A.
A1 Milani, Lili
A1 Schumacher, Johannes
A1 Woldbye, David P.
A1 Forstner, Andreas J.
A1 Nöthen, Markus M.
A1 Hovatta, Iiris
A1 Horwood, John
A1 Copeland, William E.
A1 Maes, Hermine H.
A1 McIntosh, Andrew M.
A1 Andreassen, Ole A.
A1 Zwart, John-Anker
A1 Mors, Ole
A1 Børglum, Anders D.
A1 Mortensen, Preben B.
A1 Ask, Helga
A1 Reichborn-Kjennerud, Ted
A1 Najman, Jackob M.
A1 Stein, Murray B.
A1 Gelernter, Joel
A1 Milaneschi, Yuri
A1 Penninx, Brenda W.
A1 Boomsma, Dorret I.
A1 Maron, Eduard
A1 Erhardt-Lehmann, Angelika
A1 Rück, Christian
A1 Kircher, Tilo T.
A1 Melzig, Christiane A.
A1 Alpers, Georg W.
A1 Arolt, Volker
A1 Domschke, Katharina
A1 Smoller, Jordan W.
A1 Preisig, Martin
A1 Martin, Nicholas G.
A1 Lupton, Michelle K.
A1 Luik, Annemarie I.
A1 Reif, Andreas
A1 Grabe, Hans J.
A1 Larsson, Henrik
A1 Magnusson, Patrik K.
A1 Oldehinkel, Albertine J.
A1 Hartman, Catharina A.
A1 Breen, Gerome
A1 Docherty, Anna R.
A1 Coon, Hilary
A1 Conrad, Rupert
A1 Lehto, Kelli
A1 ,
A1 Deckert, Jürgen
A1 Eley, Thalia C.
A1 Mattheisen, Manuel
A1 Hettema, John M.
YR 2024
UL http://medrxiv.org/content/early/2024/07/05/2024.07.03.24309466.abstract
AB The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder, and phobias) are highly prevalent, often onset early, persist throughout life, and cause substantial global disability. Although distinct in their clinical presentations, they likely represent differential expressions of a dysregulated threat-response system. Here we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant ANX risk variants and 66 genes with robust biological support. In an independent sample of 1,175,012 self-report ANX cases and 1,956,379 controls, 51 of the 58 associated variants were replicated. As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism, and other internalizing phenotypes. Follow-up analyses demonstrated enrichment in all major brain regions and highlighted GABAergic signaling as one potential mechanism underlying ANX genetic risk. These results advance our understanding of the genetic architecture of ANX and prioritize genes for functional follow-up studies.Competing Interest StatementPer Hoffmann receives Salary from the Life & Brain GmbH, Bonn, Germany. James L. Kennedy is a member of the Scientific Advisory Board for Myriad Neuroscience Inc. Ian B. Hickie was an inaugural Commissioner on Australia's National Mental Health Commission (2012-18). He is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney. The BMC operates an early-intervention youth services at Camperdown under contract to headspace. He is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded Project Synergy (2017-20; a three-year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies. Andrew M. Mcintosh has received research support from Eli Lilly, Janssen, and The Sackler Trust. AMM has also received speaker fees from Illumina and Janssen. Murray B. Stein has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, Boehringer Ingelheim, Bionomics, BioXcel Therapeutics, Clexio, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He is paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). He has also received research support from NIH, Department of Veterans Affairs, and the Department of Defense. He is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. Joel Gelernter is named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists" filed January 24, 2018 and issued on January 26, 2021 as U.S. Patent No. 10,900,082; and is paid for editorial work for the journal "Complex Psychiatry." Iiris Hovatta received speaker's honoraria from Lundbeck. Ole A. Andreassen received speaker's honorarium from Lundbeck and Sunovion, consultant for Cortechs.ai and Precision Health AS. Katharina Domschke has been a member of the Steering Committee Neurosciences, Janssen, Inc. until 2022 and is currently a member of the Board of the German National Society of Psychiatry (DGPPN) and the Neurotorium Editorial Board of the Lundbeck Foundation. Jordan W. Smoller is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity) and has received an honorarium for an internal seminar Tempus Labs. He is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. Eduard Maron has received research support and has also received speaker fees from Lundbeck. Hans J. Grabe has received travel grants and speakers honoraria from Indorsia, Neuraxpharm, Servier and Janssen Cilag. Henrik Larsson has served as a speaker for Evolan Pharma, Medici and Shire/Takeda and has received research grants from Shire/Takeda; all outside the submitted work. Gerome Breen is an advisory board member for Compass Pathways. Juergen Deckert is a member of the board of the German Society of Biological Psychiatry and is on the scientific advisory boards of non-profit organizations and foundations. Volker Arolt worked as an advisor for Sanofi-Adventis Germany. Zach Fuller and Xin Wang are employees of 23andMe and hold stock or stock options in 23andMe. All other authors have no competing interests to declare.Funding StatementThis work was supported by grant NIH R01MH113665 (PI: John M. Hettema) and the PGC4 grant 5R01MH124847 (MPI: PF Sullivan). Michelle K. Lupton is supported by a Boosting Dementia Leadership Fellowship [APP1140441]. Silviu-Alin Bacanu is funded by the following grants: MH113665, MH118239. Rosa Cheesman is funded by the Jacobs Foundation (no. 2023-1510-00) and the Research Council of Norway (288083). Annika B. Faucon is funded by the following grants: T32GM080178. Sarah Medland NHMRC APP1172917. Stephan Ripke 1U01MH109528 01. Swapnil Awashi has received money from the Stanley Center Gift 2020. Roseann E. Peterson is supported by NIMH R01MH125938 and The Brain & Behavior Research Foundation NARSAD grant 28632 P&S Fund. Matthew H. Iveson was supported by a Wellcome Trust Mental Health award (226770/Z/22/Z), a Medical Research Council Mental Health Data Pathfinder award (MRC-MC_PC_17209) and by the UK Research and Innovation-funded DATAMIND project (MR/W014386/1). Bendik S. Winsvold: This work was supported by the South-Eastern Norway Regional Health Authority (grant no. 2020034). Abigail R. ter Kuile was funded by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care). Daniel F. Levey was supported by an NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation and a Career Development Award CDA-2 from the Veterans Affairs Office of Research and Development (1IK2BX005058-01A2). Baptise Couvy-Duchesne is supported by a CJ Martin Fellowship, awarded by the NHMRC (app. 1161356). Sandra van der Auwera: This project was supported by the Federal Ministry of Education and Research (BMBF, gr. no 01KU2004) under the frame of ERA PerMed (TRAJECTOME project, ERAPERMED2019-108). Giovanni A. Salum is supported by the National Institute of Developmental Psychiatry for Children and Adolescents, Sao Paulo, with grants from the Sao Paulo Research Foundation (Fapesp 2014/50917-0; 2013/08531-5) and the Brazilian National Council for Scientific and Technological Development (CNPq 465550/2014-2). James L. Kennedy is supported by the Tanenbaum Family Foundation. Clement C. Zai is supported by the Brain and Behavior Research Foundation (NARSAD), CAMH Foundation. Gwyneth Zai is supported by the Brain and Behavior Research Foundation (BBRF), the Physicians' Services Incorporated (PSI) Foundation, the International OCD Foundation (IOCDF), the University of Toronto Department of Psychiatry Academic Scholars Award, and the CAMH AFP Innovation Fund.. Arun K. Tiwari is supported by the Ministry of Research and Innovation of Ontario, CAMH foundation and Canadian Institutes of Health Research. Jaakko Kaprio is supported by the Academy of Finland (grant 312073). Joseph Boden is supported by the Health Research Council of New Zealand Programme Grant 16/600. Christel M. Middeldorp: This study was funded by grants received from the National Health and Medical Research Council (NHMRC) and Australian Research Council (ARC). Fabiana L. Lopes is supported by the National Institute of Mental Health R25 MH101076. Francis J. McMahon and Nirmala Akula are supported in part by the Intramural Research Program of the NIMH (ZIAMH002843). Henning Tiemeier was supported by grant 016.VICI.170.200 from Netherlands Organization for Health Research and Development. Naomi R. Wray was supported by grant numbers NHMRC 1113400, 1173790. Enda M. Byrne was supported by the National Health and Medical Research Council grant 1145645. Glyn Lewis was supported by the Wellcome Trust 084268/Z/07/Z. UCLH BRC. Nicholas J. Timpson is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). Lea K. Davis CTSA (SD, Vanderbilt Resources): The project described was supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Nathan A Gillepsie was supported by grant R00DA023549. Work by Kristi Krebs, Lili Milani and Kelli Lehto was funded by the European Union through the European Regional Development Fund Project No. 2014-2020.4.01.15-0012 GENTRANSMED, the Estonian Research Council (PRG184, PSG615). Data analysis was carried out in part in the High-Performance Computing Center of University of Tartu. Andreas J. Forstner received funding from the Else Kroener-Fresenius-Stiftung (2019_A127). Markus M. Noethen is a member of the DFG-funded Excellence Cluster ImmunoSensation2 (EXC 2151 - 390873048). Iiris Hovetta has received support from the Sigrid Juselius Foundation. Elisa M. Tasanko has received support from the Sigrid Juselius Foundation. Hermine H. Maes: This research was supported by the National Institute on Drug Abuse (U01DA024413, R01DA025109, R01DA054313), the National Institute of Mental Health (R01MH045268, R01MH068521). Andrew M. McIntosh is supported by the Wellcome Trust (104036/Z/14/Z, 216767/Z/19/Z, 220857/Z/20/Z, 223165/Z/21/Z, 226770/Z/22/Z) and UKRI MRC (MC_PC_17209, MR/S035818/1). This work is part of a project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847776. Ole A. Andreassen has received support from KG Jebsen Stiftelsen (SKGJ-MED-021), Research Council of Norway (223273, 324252, 324499), UiO LifeScience Program, NordForsk #164218. Ted Reichborn-Kjennerud is supported by the Research Council of Norway (274611, PI: Reichborn-Kjennerud). Jacob M. Najman is supported by the National Health and Medical Research Council. Murray B. Stein is supported by the USA Department of Defense, USA Army, and NIMH. Joel Gelernter is supported by the Department of Veterans Affairs Office of Research and Development, USVA, grant I01CX001849. Dorret I. Boomsma is supported through the Royal Netherlands Academy of Science Award (KNAW PAH/6635). NWO 480-15-001/674: Netherlands Twin Registry Repository; Biobanking and Biomolecular Research Infrastructure (NWO BBMRI-NL, 184.033.111); NWO/SPI 56-464-14192, Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health, Rutgers University Cell and DNA Repository (NIMH U24 MH 068457-06), the Avera Institute, Sioux Falls (USA) and the National Institutes of Health (NIH R01 HD042157-01A1, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995) and European Research Council (ERC-230374). Christian Rueck is supported by the Swedish Research Council (2018- 02487), Swedish Research Council for Health, Working Life and Welfare ((2018-00221 and 2021-00132). Tilo T.J. Kircher & Georg W. Alpers: The study was funded by the BMBF. Volker Arolt was supported by the German Ministry of Education and Research and was funded by EU Horizon 2020 (Project MOODSTRATIFICATION). Jordan W. Smoller was supported by grant NIMH R01 MH085542. Andreas Reif is supported by DFG TR CRC 58, BMBF Panic-Net. Gerome Breen and Thalia Eley are supported by MR/V012878/1. Anna R. Docherty is supported by R01 MH123619, R01 MH123489. Hilary Coon is supported by R01MH122412, R01MH123489. Kelli Lehto is supported by the Estonian Research Council grant no PSG615. Juergen Deckert has received support by the EU, BMBF, BMEARDE and DFG. Tan-Hoang Nguyen is supported by NIAAA K25AA030072 and The Brain & Behavior Research Foundation NARSAD grant 28599. Brittany Mitchell was supported by an Australian NHMRC Investigator Grant (APP2017176). Alex S. F. Kwong was supported by an Economics and Social Research Council (ESRC) Postdoctoral Fellowship (ES/V011650/1). Brenda W. Penninx is supported by the research project 'Stress in Action', financially supported by the Dutch Research Council and the Dutch Ministry of Education, Culture and Science (NWO gravitation grant number 024.005.010). The UK Medical Research Council and Wellcome (Grant Ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grant funding is available on the ALSPAC website. Vanderbilt University Medical Center's BioVU is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding/. Generation Scotland received core funding from the Chief Scientist Office of the Scottish Government Health Directorate CZD/16/6 and the Scottish Funding Council HR03006. Genotyping of the Generation Scotland samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical Research Council and the Wellcome Trust (Reference 104036/Z/14/Z, 220857/Z/20/Z). This work has made use of the resources provided by the Edinburgh Compute and Data Facility (ECDF). (http://www.ecdf.ed.ac.uk/). MoBa thanks the Norwegian Institute of Public Health for generating high-quality genomic data. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (RCN) (#229624). We also thank the NORMENT Centre for providing genotype data, funded by the RCN (#223273), South East Norway Health Authority (SENHA) and KG Jebsen Stiftelsen. We further thank the Center for Diabetes Research, the University of Bergen for providing genotype data and performing QC and imputation of the data funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the RCN, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authorities. The RCN supported H. Ask, E. Corfield and T. Reichborn-Kjennerud (#274611, #324620). A. Havdahl L. Hannigan and E. Corfield were supported by SENHA (#2020022, #2018058, #2021045). Partial support for all datasets housed within the Utah Population Data Base is provided by the Huntsman Cancer Institute (HCI), http://www.huntsmancancer.org/, and the HCI Cancer Center Support grant, P30CA42014 from the National Cancer Institute. DNA extraction was performed by the University of Utah Center for Clinical and Translational Science supported by the National Center for Advancing Translational Sciences of the NIH (grant number UL1TR002538). The Swedish Twin Registry is managed by Karolinska Institutet and receives funding through the Swedish Research Council under the grant 2017-00641. The Gedi study was supported by the National Institute on Drug Abuse (U01DA024413, R01DA11301), the National Institute of Mental Health (R01MH063970, R01MH063671, R01MH048085, K01MH093731 and K23MH080230), NARSAD, and the William T. Grant Foundation. We are grateful to all the GSMS and CCC study participants who contributed to this work. The GEDI-VTSABD research was supported by the National Institute on Drug Abuse (U01DA024413, R01DA025109), the National Institute of Mental Health (R01MH045268, R01MH068521). We are grateful to all the VTSABD study participants who contributed to this work. The Christchurch Health and Development Study (CHDS) has been supported by funding from the Health Research Council of New Zealand, the National Child Health Research Foundation (Cure Kids), the Canterbury Medical Research Foundation, the New Zealand Lottery Grants Board, the University of Otago, the Carney Centre for Pharmacogenomics, the James Hume Bequest Fund, US National Institutes of Health grant MH077874 and National Institute on Drug Abuse grant R01DA024413. SHIP-START is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald Approach to Individualized Medicine (GANI_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the Cache Campus program of the InterSystems GmbH. The Trondelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology NTNU), Trondelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping was financed by the National Institute of health (NIH), University of Michigan, The Norwegian Research council, and Central Norway Regional Health Authority and the Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU). The genotype quality control and imputation has been conducted by the K.G. Jebsen center for genetic epidemiology, Department of public health and nursing, Faculty of medicine and health sciences, Norwegian University of Science and Technology (NTNU). The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), NIH/NIMH (1U01MH109514-01 and 1R01MH124851-01 to ADB) and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB). The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of Netherlands Organization for Health Research and Development (ZonMw, grant number: 10‐000‐1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekscentrum). The CoLaus|PsyCoLaus study was supported by unrestricted research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (grants 3200B0-105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 33CS30_177535, 3247730_204523 and 320030_220190) and the Swiss Personalized Health Network (grant 2018DRI01). The BLTS and QIMR adults samples were collected using grant funding awarded from many grant funding bodies including the Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496675, 496739, 552485, 552498, 613608), the FP-5 GenomEUtwin Project (QLG2-CT- 2002-01254), the US National Institutes of Health (NIH grants AA07535, AA10248, AA13320, AA13321, AA13326, AA14041, MH66206, DA12854, DA019951) and the Center for Inherited Disease Research, Baltimore. This also incorporated updated data collected as a part of the PISA study. PISA is funded by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Initiative - Team Grant [APP1095227]. The AGDS was primarily funded by the National Health and Medical Research Council (NHMRC) of Australia grant 1086683. This work was further supported by NHMRC grants 1145645, 1078901, 1113400 and 1087889 and NIMH. The QSkin study was funded by the NHMRC (grant numbers 1073898, 1058522 and 1123248). NGM is supported through NHMRC investigator grants (1172917, 1173790 and 1172990). PISA is funded by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Initiative - Team Grant [APP1095227]. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. TRAILS has been financially supported by various grants from Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grant 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-004; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013 and 481-11-001; NWO Vici 016.130.002 and 453-16-007/2735; NWO Gravitation 024.001.003), the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), the European Research Council (ERC-2017-STG-757364 en ERC-CoG-2015-681466), Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32), the Gratama foundation, the Jan Dekker foundation, the participating universities, and Accare Centre for Child and Adolescent Psychiatry. MUSP: This study was funded by grants received from the National Health and Medical Research Council (NHMRC) and Australian Research Council (ARC). Thalia Eley: This study presents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The PanicNet I and II studies have been funded by the BMBF. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:23andMe: Participants provided informed consent and participated in the research online under a protocol approved by the external AAHRPP-accredited IRB, Ethical & Independent Review Services (E&I Review). ALSPAC: Ethical approval was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. The study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool: http://www.bristol.ac.uk/alspac/researchers/our-data. ANGST-MGS: This study was approved by review boards at participating institutions. All subjects gave informed consent to participate in the study explanation of study protocols and objectives. ANGST-NESDA/NTR: NESDA and NTR studies were approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Center, Amsterdam. All subjects provided written informed consent. ANGST-PCL: This research was approved by the local institutional review board. All participants received a detailed description of the goal and funding of the study and signed a written consent. ANGST-RS1-RS2-RS3: The Rotterdam Study has been approved by the institutional review board (Medical Ethics Committee) of the Erasmus Medical Center and by the review board of The Netherlands Ministry of Health, Welfare and Sports. The approval has been renewed every 5 years, as well as with the introduction of major new elements in the study (e.g., MRI investigations). ANGST-SHIP-START: The ethics committee of the University of Greifswald approved this study. ANGST-TRAILS: The study was approved by the Dutch Central Committee on Research Involving Human Subjects. Participants were treated in compliance with the Declaration of Helsinki, and all measurements were carried out with their adequate understanding and written consent. BioVU: This study was reviewed by the VUMC IRB and designated as non-human subjects research because of the use of fully de-identified data (IRB# 190418 and IRB# 201609). ESTBB: The current study is approved by the Estonian Committee on Bioethics and Human Research (ref. 1.1-12/624). FinnGen: The Ethical Review Board of the Hospital District of Helsinki and Uusimaa approved the FinnGen study protocol Nr. HUS/990/2017. The FinnGen project was approved by Finnish Institute for Health and Welfare (THL), approval numbers THL/2031/6.02.00/2017, amendments THL/341/6.02.00/2018, THL/2222/6.02.00/2018 and THL/283/6.02.00/2019. All Finns can take part in the study by giving a biobank consent allowing the use of their samples. GEDI: GSMS: The study protocol and consent consent/assent forms were approved by the Duke University Medical Center Institutional Review Board. VTSABD: The study protocol and consent/assent forms were approved by the Virginia Commonwealth University Institutional Review Board. CHDS: In all cases, data have been gathered on the basis of signed and informed consent from young people and/or their parents. GSC: Written informed consent for linkage was obtained for GS:SFHS and only those individuals that provided informed consent were analyzed. HUNT: The current study is approved by the Regional Committee for Medical and Health Research Ethics (ref. 2015/575). iPSYCH: The study was approved by the Regional Scientific Ethics Committee in Denmark and the Danish Data Protection Agency. MGH-ICCBD/PBK: ICCBD & PKB: The "International Cohort Collection for Bipolar Disorder" ("ICCBD"; MGH PI Smoller; #2008P002153) and "Partners Biobank" ("PKB"; PI Smoller; #2009P002312) studies receive Human Subject IRB approval from the Massachusetts General Hospital. MoBa: The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act. The current study was approved by The Regional Committees for Medical and Health Research Ethics (20311). MUSP: Informed consent was given, and ethical approval was gained from the University of Queensland Human Research Ethics Committee 2019/HE002492, Mater Health Services Human Research Ethics Committee HREC/13/MHS/79. MVP: Consent is obtained in accordance with all VA policies and under the authority of the VA Central IRB. PANIC: Study protocols were approved by the respective ethics committees and written informed consent obtained from all participants. QIMR: All studies were approved by the Human Research Ethics Committee of QIMR. STR: The study was approved by the local ethics committee at Karolinska Institutet and all participants gave informed consent. UKBB: The full ethics borad details are found at https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics. UTAH-Suicide: This ongoing study is approved by Institutional Review Boards from the University of Utah, Intermountain Healthcare, and the Utah Department of Health.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSummary statistics excluding 23andMe will be made available on the PGC data-download page (https://pgc.unc.edu/for-researchers/download-results/). The replication GWAS summary statistics for the 23andMe data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Datasets will be made available at no cost for academic use. Please visit https://research.23andme.com/research-innovation-collaborations/ for more information and to apply to access the data.